Proteomics of Severe Traumatic Brain Injury: A Feasibility Study

Brain Injuries, Traumatic Clinical Trial

Official title:

Proteomics of Severe Traumatic Brain Injury: A Feasibility Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT00522496
• Other study ID #: 20216
• Status: Recruiting
• Phase: N/A
• First received: August 27, 2007
• Last updated: February 20, 2009
• Start date: July 2007
• Est. completion date: August 2009

Study information

• Verified date: February 2009
• Source: University of Calgary
• Contact: David A Zygun, MD
• Phone: 403-944-1691
• Email: dzygun[@]ucalgary.ca
• Is FDA regulated: No
• Health authority: Canada: Ethics Review Committee
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to:

1. Determine the temporal course of matrix metalloproteinase (MMP) expression in patients wiht severe traumatic brain injury

2. Determine the temporal course of the expression of MMP-related inflammatory mediators of secondary injury in patients with severe traumatic brain injury

3. Describe the association of physiological changes and standard microdialysis analyte measures (lactate, pyruvate, lactate/pyruvate ratio, and glucose) to MMP and neuroinflammatory marker concentrations.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 8
• Est. completion date: August 2009
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patient is 18 years of age or older

• Patient has GCS less than 9

• Patient requires intracranial pressure monitoring

• Patient life expectancy greater than 72 hours

Exclusion Criteria:

• Patient's TBI is greater than 24 hours old

• Patient is less than 18 years of age

• Patient does not require intracranial pressure monitoring

• Patient has life expectancy less than 72 hours

• Patient has GCS greater or equal to 9

• Patient is currently enrolled in another study

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Brain Injuries
• Brain Injuries, Traumatic

Locations

Country	Name	City	State
Canada	Foothills Medical Centre	Calgary	Alberta

Sponsors (2)

Lead Sponsor	Collaborator
University of Calgary	Canadian Intensive Care Foundation

Country where clinical trial is conducted

Canada,